First Wave Biopharma Hits New 52-Week High of $4.61

First Wave Biopharma, Inc. has reached a significant milestone by hitting a new 52-week high of USD 4.61 on September 16, 2025. This achievement marks a notable increase from its 52-week low of USD 0.93, reflecting a remarkable performance over the past year. The stock has demonstrated a robust 71.67% increase in value, significantly outperforming the S&P 500, which has seen a gain of 17.58% during the same period.
In the Pharmaceuticals & Biotechnology industry, First Wave Biopharma, with a market capitalization of USD 4 million, continues to navigate its financial landscape. The company currently has a debt-to-equity ratio of 0.02, indicating a low level of debt relative to its equity. However, it is important to note that the company is currently loss-making, as reflected by its negative return on equity of -40.31% and a price-to-book ratio of 0.08. As First Wave Biopharma continues to evolve, its recent stock performance highlights its position within the competitive pharmaceutical sector.